期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 116, 期 1, 页码 146-151出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-022-03309-9
关键词
Acute myelogenous leukemia; Del(5q); Decitabine; Minimally myelosuppressive regimen; Allo-hematopoietic stem cell transplantation (allo-HSCT)
类别
资金
- Jiangsu project [CXTDA2017014, BE2019672]
- Suzhou project [SS201809, GSWS2020039]
- National Clinical Research Center for Hematological Disorders [2020ZKPB02]
- NCI [CA21765]
- ALSAC
- St. Jude Departments of Oncology and Global Pediatric Medicine
Cases of pediatric acute myeloid leukemia (AML) with complex karyotypes including chromosome 5 abnormalities are rare and have a very poor prognosis. This study shows that combination therapy can effectively induce remission with good tolerability and improve survival rates in this subtype of AML patients.
Cases of pediatric acute myeloid leukemia (AML) with complex karyotypes including chromosome 5 abnormalities are rare and have a very poor prognosis. Management of AML with monosomy 5/del(5q) has been inconsistent. We treated three adolescents with this AML subtype using combined low-dose cytarabine and mitoxantrone, concurrently with decitabine and G-CSF, for remission induction. Decitabine was also included in the conditioning regimen before hematopoietic cell transplantation (HCT). All three patients achieved complete remission after treatment with this combination therapy. The treatment was well tolerated, and the patients are alive and free of disease at 3.6, 3.2, and 3.0 years after HCT, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据